Mostrar el registro sencillo del ítem
dc.contributor.author | Katsinas, Nicolaos | |
dc.contributor.author | Gehlsen, Uta | |
dc.contributor.author | García Posadas, Laura | |
dc.contributor.author | Rodríguez Rojo, Soraya | |
dc.contributor.author | Steven, Philipp | |
dc.contributor.author | González García, María Jesús | |
dc.contributor.author | Enriquez De Salamanca Aladro, Amalia | |
dc.date.accessioned | 2022-09-23T08:07:58Z | |
dc.date.available | 2022-09-23T08:07:58Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Journal of Clinical Medicine, 2022, Vol. 11, Nº. 16, 17 pp. | es |
dc.identifier.issn | 2077-0383 | es |
dc.identifier.uri | https://uvadoc.uva.es/handle/10324/55602 | |
dc.description | Producción Científica | es |
dc.description.abstract | Dry eye (DED) is a prevalent disease with immune-mediated inflammation as the principal pathophysiological etiology. Olive pomace, the major by-product of the olive oil industry, is rich in high-value polyphenols. Their anti-inflammatory and immunomodulatory activities were determined on human CD4+ T cells (hTCD4+) and in a DED animal model. The viability of hTCD4+ cells isolated from peripheral blood and activated with phytohemagglutinin-M was evaluated after treatment for 48 h with an olive pomace extract (OPT3, 0.10–0.40 mg/mL) and its major compound, hydroxytyrosol (25–100 μM). Regarding the DED animal model, 100 μM hydroxytyrosol, 0.20 mg/mL OPT3, or vehicle (borate buffer) were topically administered to 14 days-desiccating stress-exposed (constant airflow/scopolamine administration) C57BL/6 mice. Tear volume, corneal fluorescein staining (CFS), CD4+, and CD8+ T cell count in lymph nodes (flow cytometry), and IP-10 and TNF-α gene expression (qRT-PCR) in the cornea, conjunctiva, and lacrimal glands were evaluated. OPT3 (0.2–0.4 mg/mL) and hydroxytyrosol (100 μM) significantly reduced hTCD4+ proliferation. In mice, both treatments reduced lacrimal gland IP-10 gene expression. OPT3 also decreased CFS, and conjunctival IP-10 and corneal TNF-α gene expression. In lymph nodes, hydroxytyrosol reduced CD3+, OPT3, and CD8+ count. Thus, a high-value application as a promising DED protection was proposed for olive pomace. | es |
dc.format.mimetype | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Ojo - Enfermedades y defectos - Tratamiento | es |
dc.subject | Síndrome de ojo seco | |
dc.subject | Aceite de oliva | |
dc.subject | Aceite de oliva - Análisis | |
dc.subject.classification | Olive pomace | |
dc.subject.classification | Phenolic extracts | |
dc.title | Olive pomace phenolic compounds: from an agro-industrial by-product to a promising ocular surface protection for dry eye disease | es |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.holder | © 2022 The Authors | es |
dc.identifier.doi | 10.3390/jcm11164703 | es |
dc.relation.publisherversion | https://www.mdpi.com/2077-0383/11/16/4703 | es |
dc.identifier.publicationfirstpage | 1 | es |
dc.identifier.publicationissue | 16 | es |
dc.identifier.publicationlastpage | 17 | es |
dc.identifier.publicationtitle | Journal of Clinical Medicine | es |
dc.identifier.publicationvolume | 11 | es |
dc.peerreviewed | SI | es |
dc.description.project | European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Initial Training Network (ITN) “IT-DED3” (H2020-MSCA-ITN-2017) - (grant 765608) | es |
dc.description.project | Ministerio de Ciencia e Innovación y Fondo Europeo de Desarrollo Regional (FEDER) (RTI2018-094071-B-C21) | es |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/765608 | |
dc.identifier.essn | 2077-0383 | es |
dc.rights | Atribución 4.0 Internacional | * |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es |
dc.subject.unesco | 3201.09 Oftalmología |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
La licencia del ítem se describe como Atribución 4.0 Internacional